ORIC - ORIC Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

61.52M

Cash

189.6M

Avg Qtr Burn

-18.26M

Short % of Float

10.77%

Insider Ownership

14.81%

Institutional Own.

74.00%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORIC-944 (PRC2 inhibitor) Details Prostate cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-114 (EGFR/HER2 Inhibitor) Details Solid tumor/s, Advanced malignancies	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-533 (CD73 Inhibitor) Details Multiple myeloma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 (Glucocorticoid Receptor Antagonist) and nab-paclitaxel Details Solid Tumors	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 (Glucocorticoid Receptor Antagonist) + Xtandi (enzalutamide) Details Prostate Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.